港股異動丨四環醫藥(0460.HK)漲逾5% 自研產品童顏水凝嘉樂妍獲批醫療器械生產許可
格隆匯9月30日丨四環醫藥(0460.HK)連續第二次反彈,現漲逾5%,報1.63港元,總市值154億港元。四環醫藥發佈公吿,由集團自主研發生產的童顏水凝(商品名:嘉樂妍®)(2毫升╱支)於2021年9月正式獲得國家藥品監督管理局批准的醫療器械生產許可。此外,公司還發布澄清公吿稱,集團自與Hugel簽署獨家分銷協議以來,一直是Hugel在中國的長期戰略合作伙伴,集團將持續致力於保持和Hugel的長期戰略合作關係。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.